Print（PDF/131KB） Jul. 31, 2025 Finances

Notice Concerning Finance Costs

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura; Securities Code: 4506, Prime Market of TSE) announced today that it recorded finance costs for the first quarter of the fiscal year ending March 31, 2026 (from April 1, 2025 to June 30, 2025) as follows.

1.Details of Finance Costs

The Company recorded a foreign exchange loss of 6,747 million yen under finance costs for the three months ended June 30, 2025 due to recent fluctuations in foreign exchange rates. This was mainly due to the valuation of foreign currency-denominated liabilities held by its overseas subsidiaries.

2.Future Outlook

Regarding the impact of the above finance costs on the results of the Company operations, please refer to the “Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2026 [IFRS]” announced today. Since the amount will fluctuate depending on the future foreign exchange rates, the Company has not revised the financial forecasts at this time.